CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D007676: Kidney Failure, Chronic NIH

(Synonyms: Kidney Fa, Kidney Fai, Kidney Fail, Kidney Failur, Kidney Failure,, Kidney Failure,, Kidney Failure, C, Kidney Failure, Ch, Kidney Failure, Chron, Kidney Failure, Chroni, Kidney Failure, Chronic)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)


Name (Synonyms) Correlation
drug730 NO-Immunosuppressive Wiki 0.58
drug1329 less-frequency hemodialysis Wiki 0.58
drug1300 dialysis Wiki 0.58
drug147 Best Practice Wiki 0.58
drug568 Immunoglubulins Wiki 0.58
drug570 Immunosuppressive Wiki 0.58
drug1168 Tocilizumab Wiki 0.13

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.33
D003324 Coronary Artery Disease NIH 0.33
D020521 Stroke NIH 0.29
D008173 Lung Diseases, Obstructive NIH 0.26
D009369 Neoplasms, NIH 0.17
D007239 Infection NIH 0.04

Correlated HPO Terms (5)


Name (Synonyms) Correlation
HP:0001677 Coronary artery atherosclerosis HPO 0.33
HP:0006510 Chronic obstructive pulmonary disease HPO 0.33
HP:0001297 Stroke HPO 0.29
HP:0006536 Obstructive lung disease HPO 0.26
HP:0002664 Neoplasm HPO 0.17

There are 3 clinical trials

Clinical Trials


1 Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

NCT04361552 Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Chronic Renal Failure Coronary Artery Disease Diabetes Mellitus Malignant Neoplasm SARS Coronavirus 2 Infection Other: Best Practice Biological: Tocilizumab
MeSH:Infection Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Stroke Kidney Failure, Chronic Coronary Artery Disease Neoplasms
HPO:Chronic obstructive pulmonary disease Coronary artery atherosclerosis Neoplasm Obstructive lung disease Stroke

Primary Outcomes

Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

Measure: 7-day length of invasive mechanical ventilation (MV)

Time: Up to 7 days

Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: 30-day mortality rate

Time: Up to 30-day after randomization

Secondary Outcomes

Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of intensive care (ICU) transfer

Time: Up to 2 years

Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of invasive mechanical ventilation

Time: Up to 2 years

Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of tracheostomy

Time: Up to 2 years

Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

Measure: Length of ICU stay

Time: Up to 2 years

Measure: Length of hospital stay

Time: Up 2 years

2 Reduced Frequency Hemodialysis in Prevalent Patients Due to the Coronavirus Disease

Facing the unusual situation imposed by the coronavirus disease, the aim of this study is to evaluate the risk and effects of less frequent hemodialysis on prevalent patients

NCT04374058 End Stage Renal Disease Other: less-frequency hemodialysis
MeSH:Kidney Failure, Chronic

Primary Outcomes

Description: Time to all-cause and cardiovascular death

Measure: Mortality

Time: From date of beginning of the study until the date of death assessed up to 52 weeks

Secondary Outcomes

Description: Time variation of the biological parameters mentioned in the title. Repeated measurements of laboratory variables will be averaged into patient quarterly means to minimize measurement variability.

Measure: Anemia, Nutrition, Adequation of dialysis, total ultrafiltration, ultrafiltration rate,

Time: From date of beginning of the study assessed up to 52 weeks

Description: Time to first hospitalization of any cause

Measure: Hospitalization

Time: From date of beginning of the study until the date of first hospitalization assessed up to 52 weeks

Description: Time to first endovascular or quirurgical intervention of the vascular access utilized at the start of the study

Measure: Vascular Access

Time: From date of beginning of the study until the date of first intervention assessed up to 52 weeks

3 A Comparative Study of Symptom-driven Surveillance vs. Cross-sectional Serological Screening of SARS-CoV-2 Infection of Patients With End-stage Kidney Disease Receiving Renal Replacement Therapy

Starting in late 2019, the world is facing a pandemic with the SARS-CoV-2 virus. Patients with end-stage kidney disease and on treatment with renal replacement therapy are high risk patients, as they are unable to maximize social distancing. We plan to gather epidemiological data using two different diagnostic approaches. We will compare a symptom-driven screening, in combination with a nasopharyngeal swab plus computed tomography (clinical approach) against serological surveillance.

NCT04378686 SARS-CoV 2 End Stage Renal Failure on Dialysis Other: dialysis
MeSH:Kidney Failure, Chronic

Primary Outcomes

Description: serology to test for IgG and IgM antibodies against SARS-CoV-2

Measure: Antibodies against SARS-CoV-2

Time: one year


HPO Nodes